Patents by Inventor Omar Quraishi
Omar Quraishi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210072266Abstract: A human insulin-like growth factor (IGF) binding protein stock solution and method of making the same include a non-recombinant human IGF binding protein-3 (nr-IGFBP-3) in an aqueous buffered medium. The concentration of the nr-IGFBP-3 in the stock solution ranges from about 16 micrograms per milliliter (?g/ml) to about 40 ?g/ml. A kit includes a set of calibrators for nr-IGFBP-3. The set of calibrators includes the nr-IGFBP-3 in different concentrations.Type: ApplicationFiled: November 16, 2020Publication date: March 11, 2021Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Spencer Lin, Kwasi Osae-Kwapong, Omar Quraishi, Seema Sinha, Michele Smith, SunRay DiFrancesco, Ryan Spears, Dharini Rawal, Debra Hovanec-Burns, Robert Owens
-
Publication number: 20190018025Abstract: A human insulin-like growth factor (IGF) binding protein stock solution and method of making the same include a non-recombinant human IGF binding protein-3 (nr-IGFBP-3) in an aqueous buffered medium. The concentration of the nr-IGFBP-3 in the stock solution ranges from about 16 micrograms per milliliter (?g/ml) to about 40 ?g/ml. A kit includes a set of calibrators for nr-IGFBP-3. The set of calibrators includes the nr-IGFBP-3 in different concentrations that are within a range of from about 0.5 ?g/ml to about 16 ?g/ml, which is configured to span a suspected range of IGFBP-3 analyte levels in an immunoassay of patient samples.Type: ApplicationFiled: December 28, 2016Publication date: January 17, 2019Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Spencer Lin, Kwasi Osae-Kwapong, Omar Quraishi, Seema Sinha, Michele Smith, SunRay DiFrancesco, Ryan Spears, Dharini Rawal, Debra Hovanec-Burns, Robert Owens
-
Publication number: 20120065369Abstract: This invention relates to enfuvirtide peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to enfuvirtide derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.Type: ApplicationFiled: March 14, 2011Publication date: March 15, 2012Inventor: OMAR QURAISHI
-
Publication number: 20120022234Abstract: The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto a hydrophobic support equilibrated in aqueous buffer having a high salt content; applying to the support a gradient of decreasing salt concentration; and collecting the eluted albumin conjugate.Type: ApplicationFiled: September 17, 2010Publication date: January 26, 2012Inventors: Nathalie Bousquet-Gagnon, Omar Quraishi, Dominique P. Bridon
-
Publication number: 20110313132Abstract: The present invention provides processes for the production of preformed albumin conjugates. In particular, the invention provides processes for the in-vitro conjugation of a therapeutic compound to recombinant albumin, wherein a therapeutic compound comprising a reactive group is contacted to recombinant albumin in solution to form a conjugate. The processes provide for conjugation to albumin species of increasing homogeneity. The resulting conjugate is purified by chromatography, in particular hydrophobic interaction chromatography comprising phenyl sepharose and butyl sepharose chromatography.Type: ApplicationFiled: March 14, 2011Publication date: December 22, 2011Inventors: Dominique P. BRIDON, Nathalie BOUSQUET-GAGNON, Omar QURAISHI
-
Publication number: 20090186819Abstract: The present invention provides pharmaceutical formulations comprising insulinotropic peptide conjugates, particularly a conjugate of albumin to exendin-4, or a derivative thereof, and methods of administration thereof. The present invention also provides methods for treating diabetes and insulinotropic peptides related diseases or conditions by administering the pharmaceutical formulations described herein.Type: ApplicationFiled: December 11, 2008Publication date: July 23, 2009Inventors: Marieve Carrier, Byeong Seon Chang, Omar Quraishi, Thomas R. Ulich, Maggie Wang, Jean-Philippe Estradier
-
Publication number: 20090088378Abstract: This invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory synctial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.Type: ApplicationFiled: May 16, 2008Publication date: April 2, 2009Inventors: Omar Quraishi, Cheryl A. Stoddart, Paul L. Black
-
Publication number: 20090088377Abstract: This invention relates to C34 peptide derivatives having improved aqueous solubility that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory synctial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.Type: ApplicationFiled: May 16, 2008Publication date: April 2, 2009Applicant: CONJUCHEM BIOTECHNOLOGIES, INC.Inventors: Omar Quraishi, Martin Robitaille, Dominique P. Bridon
-
Publication number: 20090054332Abstract: The present invention relates to compounds comprising modified thrombopoietin peptides and conjugates of such modified peptides to serum components, typically serum proteins or peptides. The compounds and conjugates of the invention comprise a reactive group or a residue of a reactive group, which is covalently attached to a modified peptide, optionally through a linking group. The present invention also provides methods for the covalent attachment of a modified peptide to a serum protein or peptide to form a conjugate of the invention. The conjugates of the invention typically exhibit a longer in vivo circulating half-life compared to the corresponding unconjugated peptides. The conjugates of the invention also retain at least some of the biological activity of the unconjugated peptides, and typically exhibit increased biological activity compared to the unconjugated peptides.Type: ApplicationFiled: June 21, 2008Publication date: February 26, 2009Applicant: CONJUCHEM BIOTECHNOLOGIES, INC.Inventors: Jean-Philippe Estradier, Martin Robitaille, Karen Thibaudeau, Dominique P. Bridon, Xicai Huang, Omar Quraishi, Nathalie Bousquet-Gagnon
-
Publication number: 20080312415Abstract: This invention relates to enfuvirtide peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to enfuvirtide derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.Type: ApplicationFiled: December 26, 2007Publication date: December 18, 2008Applicant: ConjuChem Biotechnologies Inc.Inventor: Omar Quraishi
-
Publication number: 20080146783Abstract: The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto a hydrophobic support equilibrated in aqueous buffer having a high salt content; applying to the support a gradient of decreasing salt concentration; and collecting the eluted albumin conjugate.Type: ApplicationFiled: October 30, 2007Publication date: June 19, 2008Inventors: Nathalie Bousquet-Gagnon, Omar Quraishi, Dominique P. Bridon
-
Publication number: 20080039532Abstract: The present application relates to a compound having a formula 1: B—R1-R2-M wherein B is a binding element for recognizing and binding a target; R1 is a first group of atoms for reacting with a functionality of the target so as to form a covalent bond with the target; R2 is a second group of atoms; R1 and R2 being such that the formation of the covalent bond between R1 and the target generates cleavage of the bond between R1 and R2 so as to free R2-M; and M is selected from the group consisting of a hydrogen atom and a pharmaceutically acceptable moiety. Alternatively, R1 and R2 can be inverted to form the formula II: B—R2-R1-M and being such that the formation of the covalent bond between R1 and the target generates cleavage of the bond between R1 and R2 so as to free R2-B.Type: ApplicationFiled: May 6, 2005Publication date: February 14, 2008Inventors: Dominique Bridon, Nathalie Bousquet-Gagnon, Xicai Huang, Omar Quraishi
-
Patent number: 7307148Abstract: The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto a hydrophobic support equilibrated in aqueous buffer having a high salt content; applying to the support a gradient of decreasing salt concentration; and collecting the eluted albumin conjugate.Type: GrantFiled: April 22, 2005Date of Patent: December 11, 2007Assignee: ConjuChem Biotechnologies Inc.Inventors: Nathalie Bousquet-Gagnon, Omar Quraishi, Dominique P. Bridon
-
Publication number: 20070269863Abstract: The present invention provides processes for the production of preformed albumin conjugates. In particular, the invention provides processes for the in-vitro conjugation of a therapeutic compound to recombinant albumin, wherein a therapeutic compound comprising a reactive group is contacted to recombinant albumin in solution to form a conjugate. The processes provide for conjugation to albumin species of increasing homogeneity. The resulting conjugate is purified by chromatography, in particular hydrophobic interaction chromatography comprising phenyl sepharose and butyl sepharose chromatography.Type: ApplicationFiled: December 22, 2006Publication date: November 22, 2007Inventors: Dominique Bridon, Nathalie Bousquet-Gagnon, Omar Quraishi
-
Publication number: 20050267293Abstract: The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto a hydrophobic support equilibrated in aqueous buffer having a high salt content; applying to the support a gradient of decreasing salt concentration; and collecting the eluted albumin conjugate.Type: ApplicationFiled: April 22, 2005Publication date: December 1, 2005Applicant: ConjuChem, Inc.Inventors: Nathalie Bousquet-Gagnon, Omar Quraishi, Dominique Bridon